Dandan Xu - Search Results

Year	Number of Results
2008	2
2009	1
2010	2
2011	2
2012	12
2013	10
2014	13
2015	18
2016	18
2017	34
2018	53
2019	49
2020	45
2021	56
2022	59
2023	15

1

Gain-of-function mutant p53 in cancer progression and therapy.

Zhang C, Liu J, Xu D, Zhang T, Hu W, Feng Z. Zhang C, et al. Among authors: xu d. J Mol Cell Biol. 2020 Sep 1;12(9):674-687. doi: 10.1093/jmcb/mjaa040. J Mol Cell Biol. 2020. PMID: 32722796 Free PMC article. Review.

2

Stem cell programs in cancer initiation, progression, and therapy resistance.

Huang T, Song X, Xu D, Tiek D, Goenka A, Wu B, Sastry N, Hu B, Cheng SY. Huang T, et al. Among authors: xu d. Theranostics. 2020 Jul 9;10(19):8721-8743. doi: 10.7150/thno.41648. eCollection 2020. Theranostics. 2020. PMID: 32754274 Free PMC article. Review.

3

Molecular Characteristics, Clinical Implication, and Cancer Immunity Interactions of Pyroptosis-Related Genes in Breast Cancer.

Xu D, Ji Z, Qiang L. Xu D, et al. Front Med (Lausanne). 2021 Sep 13;8:702638. doi: 10.3389/fmed.2021.702638. eCollection 2021. Front Med (Lausanne). 2021. PMID: 34589498 Free PMC article.

4

Fission Yeast Autophagy Machinery.

Xu DD, Du LL. Xu DD, et al. Cells. 2022 Mar 24;11(7):1086. doi: 10.3390/cells11071086. Cells. 2022. PMID: 35406650 Free PMC article. Review.

5

Orexin-A alleviates astrocytic apoptosis and inflammation via inhibiting OX1R-mediated NF-κB and MAPK signaling pathways in cerebral ischemia/reperfusion injury.

Xu D, Kong T, Shao Z, Liu M, Zhang R, Zhang S, Kong Q, Chen J, Cheng B, Wang C. Xu D, et al. Biochim Biophys Acta Mol Basis Dis. 2021 Nov 1;1867(11):166230. doi: 10.1016/j.bbadis.2021.166230. Epub 2021 Aug 4. Biochim Biophys Acta Mol Basis Dis. 2021. PMID: 34358627 Free article.

6

Bioinformatics Analysis Reveals the Potential Diagnostic Biomarkers for Abdominal Aortic Aneurysm.

Xie X, Wang EC, Xu D, Shu X, Zhao YF, Guo D, Fu W, Wang L. Xie X, et al. Among authors: xu d. Front Cardiovasc Med. 2021 Jul 20;8:656263. doi: 10.3389/fcvm.2021.656263. eCollection 2021. Front Cardiovasc Med. 2021. PMID: 34355024 Free PMC article.

7

Smartphone-based analytical biosensors.

Huang X , Xu D , Chen J , Liu J , Li Y , Song J , Ma X , Guo J . Huang X , et al. Among authors: xu d. Analyst. 2018 Nov 5;143(22):5339-5351. doi: 10.1039/c8an01269e. Analyst. 2018. PMID: 30327808 Review.

8

The Anti-fibrosis drug Pirfenidone modifies the immunosuppressive tumor microenvironment and prevents the progression of renal cell carcinoma by inhibiting tumor autocrine TGF-β.

Wang G, Zhou X, Guo Z, Huang N, Li J, Lv Y, Han L, Zheng W, Xu D, Chai D, Li H, Li L, Zheng J. Wang G, et al. Among authors: xu d. Cancer Biol Ther. 2022 Dec 31;23(1):150-162. doi: 10.1080/15384047.2022.2035629. Cancer Biol Ther. 2022. PMID: 35130111 Free PMC article.

9

Lnc-EST12, which is negatively regulated by mycobacterial EST12, suppresses antimycobacterial innate immunity through its interaction with FUBP3.

Yao Q, Xie Y, Xu D, Qu Z, Wu J, Zhou Y, Wei Y, Xiong H, Zhang XL. Yao Q, et al. Among authors: xu d. Cell Mol Immunol. 2022 Aug;19(8):883-897. doi: 10.1038/s41423-022-00878-x. Epub 2022 May 30. Cell Mol Immunol. 2022. PMID: 35637281 Free PMC article.

10

Immuno-genomic characterisation of high-grade serous ovarian cancer reveals immune evasion mechanisms and identifies an immunological subtype with a favourable prognosis and improved therapeutic efficacy.

Sun J, Yan C, Xu D, Zhang Z, Li K, Li X, Zhou M, Hao D. Sun J, et al. Among authors: xu d. Br J Cancer. 2022 Jun;126(11):1570-1580. doi: 10.1038/s41416-021-01692-4. Epub 2022 Jan 11. Br J Cancer. 2022. PMID: 35017656 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results